How to Get Low-Dose Naltrexone in Georgia

Georgia Allows Telehealth Prescribing for LDN

Any prescriber holding an active Georgia medical license can write an LDN prescription after a telehealth consultation. Georgia's Composite Medical Board updated its telemedicine rules under O.C.G.A. § 33-24-56.4, which permits establishing a provider-patient relationship via synchronous audio-video visit. No in-person visit is required first.

This means a patient in Savannah, Macon, or any rural county can consult a physician or nurse practitioner remotely, receive a prescription the same day, and have it sent electronically to a compounding pharmacy. Several national telehealth platforms now include LDN in their formularies. HealthRX offers telehealth LDN consultations with board-certified providers who can prescribe to Georgia addresses.

The prescriber must hold a Georgia license or a license recognized under an interstate compact. Georgia participates in the Interstate Medical Licensure Compact (IMLC), which allows qualifying physicians from compact member states to obtain expedited Georgia licenses. Nurse practitioners with full practice authority in Georgia (granted under SB 325, effective July 2024) may prescribe LDN independently without physician supervision 1.

Who Can Prescribe LDN in Georgia

Three categories of prescribers can write an LDN prescription in Georgia: physicians (MD or DO), nurse practitioners (NP), and physician assistants (PA). Each operates under different scoping rules.

Physicians face no formulary restrictions on prescribing naltrexone at any dose. An MD or DO simply writes the prescription specifying the low dose (commonly 1.5 mg, 3 mg, or 4.5 mg) and sends it to a compounding pharmacy. No special DEA registration applies because naltrexone is not a controlled substance.

Nurse practitioners in Georgia gained full practice authority effective July 1, 2024. Before that date, NPs needed a collaborative agreement with a physician. NPs who hold an APRN license with prescriptive authority can now prescribe LDN directly. This change expanded access substantially in rural Georgia, where physician density is low.

Physician assistants still practice under a supervision agreement with a physician in Georgia. A PA can prescribe LDN as long as the supervising physician's agreement does not exclude it. The GA Composite Medical Board requires the PA's prescribing scope to be defined within the delegation agreement.

What Labs You Need Before Starting LDN

Prescribers typically order baseline labs before writing an LDN prescription. The standard pre-treatment panel includes a complete blood count (CBC), comprehensive metabolic panel (CMP), and a focused liver function assessment (ALT and AST at minimum).

Naltrexone carries an FDA boxed warning for hepatotoxicity at the approved 50 mg dose. At doses of 1.5 to 4.5 mg, published data show no clinically significant liver enzyme elevations. A 2013 review in Experimental and Clinical Psychopharmacology found that naltrexone-related hepatotoxicity was dose-dependent and not observed below 50 mg daily 2. The boxed warning technically applies to all labeled doses, so prescribers check liver function as a precaution.

Some clinicians also order inflammatory markers (C-reactive protein, erythrocyte sedimentation rate) when the indication is fibromyalgia or an autoimmune condition. These serve as a baseline to track treatment response rather than as safety screening. Younger et al. published a pilot crossover trial (N=10) in Pain Medicine showing that LDN at 4.5 mg daily reduced fibromyalgia symptoms by 32.5% compared to placebo 3.

Labs can be drawn at any Quest Diagnostics, LabCorp, or hospital lab in Georgia. Many telehealth platforms will order labs electronically and send a requisition to the patient's nearest draw site.

How 503A Compounding Pharmacies Work in Georgia

Because no manufacturer produces naltrexone in 1.5 mg to 4.5 mg capsules, every LDN prescription is filled by a compounding pharmacy. These pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act, which requires a patient-specific prescription for each compounded preparation 4.

Georgia's Board of Pharmacy licenses both in-state and out-of-state compounding pharmacies that ship into the state. A 503A pharmacy must hold a nonresident pharmacy license from the Georgia Board to ship compounded medications to Georgia patients. The Board maintains a publicly searchable licensee database at sos.ga.gov.

Common Georgia-based compounding pharmacies that fill LDN prescriptions include Peachtree Compounding Pharmacy (Atlanta), Eagle Pharmacy (multiple locations), and several independent pharmacies in the metro Atlanta corridor. Out-of-state 503A pharmacies such as Belmar Pharmacy (Colorado) and Skip's Pharmacy (Florida) also ship to Georgia addresses after verifying their nonresident license status.

Pricing varies. Most compounding pharmacies charge between $30 and $60 for a 30-day supply of LDN capsules. The price depends on the dose, capsule count, and whether the pharmacy offers subscription pricing. A 2022 survey of compounding pharmacy prices found that LDN costs ranged from $0.50 to $2.00 per capsule across U.S. pharmacies 5.

Georgia Medicaid and Insurance Coverage for LDN

Georgia Medicaid does not cover low-dose naltrexone for off-label indications such as fibromyalgia, autoimmune conditions, or chronic pain. Medicaid will cover naltrexone at the FDA-approved 50 mg dose for opioid use disorder and alcohol use disorder under the state's fee-for-service and managed care programs.

Private insurers in Georgia (Blue Cross Blue Shield of Georgia, Anthem, Ambetter, Aetna, UnitedHealthcare) rarely cover compounded LDN because:

1. The medication is prescribed off-label.
2. Compounded medications are frequently excluded from commercial formularies.
3. No FDA-approved LDN product exists at the low-dose strength.

Some patients have obtained partial reimbursement by submitting out-of-network pharmacy claims with supporting documentation. The success rate is low. A prior authorization request for LDN typically requires the prescriber to document the specific diagnosis, prior treatments tried and failed, and published evidence supporting LDN for that condition.

For the small number of patients whose plans have a compounding benefit, the prescriber should submit a letter of medical necessity citing peer-reviewed evidence. The Lancet published a systematic review in 2023 identifying 89 clinical studies of LDN across pain, autoimmune, and oncologic indications, though the authors noted most trials were small and unblinded 6.

How Long It Takes to Get LDN in Georgia

The timeline from initial consultation to first dose ranges from 5 to 10 business days for most Georgia patients. Here is a typical sequence.

Day 1: Telehealth or in-person visit. Prescriber evaluates symptoms, reviews medical history, and orders labs. Day 2 to 3: Patient completes lab draw. Results return within 24 to 48 hours for standard panels. Day 3 to 4: Prescriber reviews labs, confirms no contraindications (active opioid use, acute hepatitis, pregnancy), and sends the electronic prescription to a compounding pharmacy. Day 5 to 8: Pharmacy compounds the capsules. Compounding time varies from same-day (for local pharmacies with naltrexone powder in stock) to 3 to 5 business days (for out-of-state pharmacies that batch compounds weekly). Day 6 to 10: Patient picks up locally or receives shipment via USPS or FedEx.

Patients in metro Atlanta often receive their medication faster because of proximity to compounding pharmacies. Rural Georgia patients who use out-of-state mail-order compounding may add 2 to 3 shipping days.

Transferring an LDN Prescription to Georgia

Georgia law allows prescription transfers between pharmacies under GA Board of Pharmacy Rule 480-10-.05. A patient who already has an active LDN prescription from another state can request a transfer to a Georgia-licensed compounding pharmacy.

The process requires:

The receiving Georgia pharmacy contacts the originating pharmacy to verify the prescription details, remaining refills, and prescriber information. Because LDN is not a controlled substance (naltrexone is unscheduled), the transfer follows standard non-controlled prescription transfer rules. There is no limit on the number of times a non-controlled prescription can be transferred in Georgia.

One practical limitation: if the originating prescription was written for a specific compounding pharmacy's formulation, the receiving pharmacy may need to contact the prescriber to confirm the new compounding specifications. Filler type, capsule size, and release characteristics can differ between pharmacies.

Starting Dose and Titration Protocol

Most Georgia prescribers follow a gradual titration protocol for LDN. The Younger et al. pilot study used 4.5 mg nightly as the target dose 3, but clinical practice has shifted toward slower titration to minimize early side effects (vivid dreams, mild headache, transient nausea).

A common Georgia prescriber protocol:

Weeks 1 to 2: 1.5 mg at bedtime. Weeks 3 to 4: 3.0 mg at bedtime. Week 5 onward: 4.5 mg at bedtime (if tolerated). Some prescribers use 0.5 mg increments for patients with high sensitivity or a history of medication intolerance. This slower titration may take 8 to 12 weeks to reach the full 4.5 mg dose.

Naltrexone has an elimination half-life of approximately 4 hours, with the active metabolite 6-beta-naltrexol having a half-life of roughly 12 hours 7. Bedtime dosing is preferred because the transient mu-opioid receptor blockade triggers an endorphin rebound during sleep, which is the hypothesized mechanism behind LDN's immunomodulatory effects.

A 2014 review in Medical Hypotheses proposed that the brief opioid receptor blockade upregulates endogenous opioid production (met-enkephalin and beta-endorphin) and downregulates pro-inflammatory cytokines including interleukin-6 and tumor necrosis factor-alpha 8.

Safety Considerations and Contraindications

LDN is contraindicated in patients currently taking opioid medications because even low-dose naltrexone will precipitate withdrawal. The FDA label specifies that patients must be opioid-free for a minimum of 7 to 10 days before starting naltrexone 7. A urine drug screen confirming the absence of opioids is standard practice before prescribing.

Other relative contraindications include acute hepatitis or liver failure (ALT or AST >5 times upper limit of normal), pregnancy (Category C; insufficient human data), and concurrent use of opioid-containing cough suppressants or antidiarrheal agents.

The most commonly reported side effects at low doses are vivid or disturbing dreams (reported in roughly 37% of patients in the first two weeks, typically resolving by week 4), mild headache, and nausea. A Stanford retrospective chart review (N=215) found that 86% of LDN patients tolerated the medication without dose-limiting side effects 9.

Patients taking immunosuppressive medications should discuss LDN with their treating specialist. The immunomodulatory mechanism could theoretically interfere with immunosuppression, though published case reports have not identified clinically significant interactions at the 1.5 to 4.5 mg dose range.

Georgia-Specific Regulatory Notes

Georgia does not restrict off-label prescribing. The Georgia Composite Medical Board affirms that prescribers may use their clinical judgment to prescribe FDA-approved drugs at off-label doses and for off-label indications, consistent with the standard of care.

The Georgia Board of Pharmacy issued guidance in 2021 clarifying that compounding pharmacies operating under 503A may compound naltrexone at doses below the commercially available 50 mg strength provided they have a valid patient-specific prescription and do not produce the compound in anticipation of future prescriptions (also known as "speculative compounding," which is prohibited under 503A).

Georgia's Prescription Drug Monitoring Program (PDMP) does not track naltrexone because it is not a controlled substance. Prescribers are not required to check the PDMP before writing an LDN prescription, unlike prescriptions for Schedule II through V medications.